Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
Want to see AUTL full AI Analyst Report?
Top Page
Autolus Therapeutics
(NASDAQ:AUTL)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▲(1.35% Upside)
Action:ReiteratedDate:04/09/26
The score is held down primarily by weak financial performance (large losses, negative gross profit, and rising cash burn with a shrinking equity cushion). Offsetting this is a relatively constructive earnings outlook with reiterated 2026 revenue guidance and expected positive gross margins, while technicals remain weak-to-neutral and valuation is difficult to assess meaningfully due to negative earnings and no dividend support.
Positive Factors
Commercial launch momentum
AUCATZYL's first full commercial year generated meaningful revenue, evidencing real market uptake, payer engagement, and operational sales capability. This establishes a revenue base that can scale toward 2026 guidance, supports commercial infrastructure investments, and is a durable foundation for margin improvement if volume and pricing trends persist.
Negative Factors
Large cash burn
Sustained, large negative operating cash flow materially shortens runway and increases reliance on execution, milestone receipts, or external financing. With cash roughly halved year-over-year, funding risk is structural: failure to hit revenue or margin milestones would likely force dilution or spending cuts, constraining long-term growth and R&D programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial launch momentum
AUCATZYL's first full commercial year generated meaningful revenue, evidencing real market uptake, payer engagement, and operational sales capability. This establishes a revenue base that can scale toward 2026 guidance, supports commercial infrastructure investments, and is a durable foundation for margin improvement if volume and pricing trends persist.
Read all positive factors
Autolus Therapeutics (AUTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$391.23M
Dividend YieldN/A
Average Volume (3M)1.66M
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth407.86%
EPS Growth30.35%
CountryUS
Employees647
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding266,143,280
10 Day Avg. Volume1,444,413
30 Day Avg. Volume1,660,506
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.75
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue8.55
Enterprise Value/Gross Profit-30.70
Enterprise Value/Ebitda-2.58
Forecast
1Y Price Target
$9.67Price Target Upside553.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$133.03M
Autolus Therapeutics Business Overview & Revenue Model
Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investig...
How the Company Makes Money
null...
Autolus Therapeutics Earnings Call Summary
Earnings Call Date:Mar 27, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but constructive picture: strong commercial launch momentum for AUCATZYL with $74.3M 2025 product sales, robust real-world efficacy and safety (ROCCA), regulatory approvals, and an active, value-creating clinical pipeline and clear guidance for 2026 revenue growth and positive gross margins. Offsetting these positives are materially higher costs in Q4, a large year-over-year increase in net loss, a nearly 49% decline in cash balance to $300.7M, and limited near-term expansion in EU revenues. The company is prioritizing scale and operating efficiencies and expects cash to fund operations into Q4 2027, but execution on margin improvements, enrollment/readouts, and potential financing or revenue realization will be critical.Positive Updates
Successful first full year commercial launch of AUCATZYL
Net product revenue of $74.3M for full year 2025; Q4 2025 net product revenue $23.3M and total Q4 revenue $24.3M (includes $1M license milestone). Company reiterated 2026 net revenue guidance of $120M to $135M (implies ~61.5% to ~81.7% growth vs 2025).
Negative Updates
Large increase in reported net loss in Q4 2025
Net loss for Q4 2025 was $90.3M versus $27.6M in Q4 2024, an increase in loss of $62.7M (≈227% increase vs prior year quarter), reflecting commercialization costs and other items.
Read all updates
Q4-2025 Updates
Positive
Negative
Successful first full year commercial launch of AUCATZYL
Net product revenue of $74.3M for full year 2025; Q4 2025 net product revenue $23.3M and total Q4 revenue $24.3M (includes $1M license milestone). Company reiterated 2026 net revenue guidance of $120M to $135M (implies ~61.5% to ~81.7% growth vs 2025).
Read all positive updates
Company Guidance
Autolus reiterated 2026 AUCATZYL net revenue guidance of $120–$135 million and expects to shift to positive gross margins in 2026 as volumes and operating efficiencies improve, while targeting more than 80 activated centers by year-end 2026 (up from 67 at end‑2025) and not planning material EU revenue outside the U.S. and U.K. in 2026. For context, 2025 was the first full year of launch with $74.3M in net product revenue (Q4 net product revenue $23.3M; total Q4 revenue $24.3M including $1.0M license revenue), Q4 cost of sales $25.3M, Q4 R&D $35.6M, Q4 SG&A $35.8M, Q4 loss from operations $72.5M and Q4 net loss $90.3M; cash and marketable securities were $300.7M at 12/31/2025 (vs. $588M at 12/31/2024) and are expected to fund operations into Q4 2027 (impacted by a delayed ~$18.6M U.K. R&D tax credit). The company also refined its accounting to recognize full product revenue and associated COGS upon confirmation of the second dose (eliminating the prior 50/50 split and deferred revenue treatment).Autolus Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 75.56M | 10.12M | 1.70M | 6.19M | 1.51M |
| Gross Profit | -21.03M | -130.90M | 1.70M | 6.19M | 1.51M |
| EBITDA | -271.60M | -233.07M | -156.77M | -132.24M | -132.47M |
| Net Income | -287.53M | -220.66M | -208.38M | -148.84M | -142.10M |
Balance Sheet | |||||
| Total Assets | 589.07M | 782.73M | 375.38M | 490.27M | 405.56M |
| Cash, Cash Equivalents and Short-Term Investments | 300.71M | 588.02M | 239.57M | 382.44M | 310.34M |
| Total Debt | 351.59M | 52.63M | 52.97M | 24.26M | 68.01M |
| Total Liabilities | 410.94M | 355.40M | 263.91M | 191.60M | 92.24M |
| Stockholders Equity | 178.13M | 427.32M | 111.47M | 298.67M | 313.32M |
Cash Flow | |||||
| Free Cash Flow | -303.32M | -241.09M | -156.57M | -123.15M | -126.72M |
| Operating Cash Flow | -283.57M | -206.27M | -145.59M | -112.31M | -117.86M |
| Investing Cash Flow | 158.46M | -394.55M | -10.99M | -10.84M | -8.86M |
| Financing Cash Flow | -4.34M | 589.55M | -883.00K | 223.61M | 284.06M |
Autolus Therapeutics Technical Analysis
Positive
1.48
Price Trends
1.48
Negative
1.52
Negative
1.67
Negative
Market Momentum
>-0.01
Negative
53.34
Neutral
67.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.39, below the 50-day MA of 1.48, and below the 200-day MA of 1.67, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.34 is Neutral, neither overbought nor oversold. The STOCH value of 67.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUTL.
Autolus Therapeutics Risk Analysis
Autolus Therapeutics disclosed 86 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We expect to continue to expand our development, commercial and regulatory capabilities and have recently developed sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. Q3, 2024
2.
The incidence and prevalence for target patient populations for AUCATZYL and our other product candidates have not been established with precision. If the market opportunities for AUCATZYL and our other product candidates are smaller than we estimate, our revenue and ability to achieve profitability will be adversely affected, possibly materially. Q3, 2024
3.
We, and the third parties on whom we rely in part for sales, marketing and distribution capabilities, may not be able to effectively market, sell and distribute AUCATZYL or our other product candidates, if approved. Q3, 2024
Autolus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $339.46M | -11.41 | -77.62% | ― | ― | -29.73% | |
52 Neutral | $504.87M | -1.68 | -137.70% | ― | ― | -67.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $494.54M | -5.28 | -30.40% | ― | ― | -100.71% | |
49 Neutral | $412.25M | -13.08 | -38.92% | ― | ― | 80.95% | |
48 Neutral | $391.23M | -1.84 | -99.00% | ― | 407.86% | 30.35% | |
41 Neutral | $28.52M | -1.38 | -135.79% | ― | -53.67% | 86.75% |
* Healthcare Sector Average
AUTL
Autolus Therapeutics
1.48
0.13
9.63%
TVRD
Tvardi Therapeutics
3.16
-15.09
-82.68%
LRMR
Larimar Therapeutics
4.87
3.03
164.67%
BNTC
Benitec Biopharma
13.25
-0.39
-2.89%
DMAC
Diamedica Therapeutics
6.54
3.07
88.47%
CTNM
Contineum Therapeutics, Inc. Class A
12.97
8.59
196.12%
Autolus Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Autolus Highlights ALL Opportunity and AUCATZYL CAR-T Platform
Positive
Apr 8, 2026
On April 8, 2026, Autolus Therapeutics hosted a virtual investor event titled “Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business” to highlight the clinical landscape, unmet needs and commercial opportunity in adult and pedia...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Autolus Highlights AUCATZYL Launch and Pipeline Advancements
Positive
Mar 27, 2026
Autolus Therapeutics reported fourth-quarter 2025 net product revenue of $23.3 million and full-year 2025 revenue of $74.3 million from AUCATZYL, driven by its first year of U.S. launch in adult relapsed or refractory B‑ALL, and confirmed th...
Business Operations and Strategy
Autolus Therapeutics Signs Long-Term Lentiviral Supply Agreement
Positive
Jan 26, 2026
On January 21, 2026, Autolus Limited, a subsidiary of Autolus Therapeutics, entered into a new ten-year Master Service Agreement with AGC Biologics S.p.A. for the manufacture and supply of lentiviral vectors, replacing a prior arrangement between ...
Business Operations and StrategyFinancial Disclosures
Autolus issues 2025 AUCATZYL results and 2026 outlook
Positive
Jan 12, 2026
On January 12, 2026, Autolus reported preliminary unaudited net product revenue from AUCATZYL of about $24 million for the fourth quarter of 2025 and approximately $75 million for full-year 2025, the first year of commercial sales, supported by a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.